The new US Administration’s impact on healthcare and life sciences

Our US webinar series continues. In this webinar, we explored the impact of the new US administration on the healthcare and life sciences sector.

The second election of President Trump has introduced a series of significant changes impacting the healthcare and life sciences sector. These changes bring a range of economic, geopolitical, trade, and regulatory challenges that extend beyond US businesses and policymakers, especially given President Trump's prior emphasis on protectionist measures, including his "America First" policy. Key developments to date include the nomination of Robert F. Kennedy Jr. as head of the Department of Health and Human Services, the U.S. withdrawal from the World Health Organization, and substantial layoffs at the FDA affecting medical device regulation. Additionally, President Trump's proposed tariffs on pharmaceutical imports from the EU and China, potential reforms of drug pricing, Medicare negotiations, and a repeated desire to repatriate the operations of US-headquartered life sciences and medical devices businesses will have global impacts. All of this is creating a blend of opportunities and challenges, with profound implications for global players in the healthcare and life sciences sector.

Covered topics:

• Key healthcare policies from the US
• Potential supply chain disruptions and impact of tariff measures with a spotlight on China and Ireland
• Potential impact on M&A activity

Speakers:

• Brian Platton of Holland & Knight
• David Brangam, Partner, Ireland
• Richard Li, Partner, China
• Lydia Torne, Partner, UK